Gland Pharma Appoints Srinivas Sadu as Executive Chairman & CEO

Per the pharma company, under Sadu's leadership, it has consistently achieved remarkable growth in revenue and profits while expanding its presence across various geographic regions.

Gland Pharma has recently named Srinivas Sadu, the incumbent MD and CEO, as the executive chairman and CEO of the company, effective June 10, 2024.

A seasoned professional with over two decades of extensive experience, Sadu has played a pivotal role in Gland's journey. He assumed the position of MD and CEO on April 25, 2019, and has been instrumental in driving the company's growth and success.

Having commenced his career with Gland Pharma in 2000, Sadu steadily climbed the corporate ladder, attaining the position of COO in 2011.

His academic background includes a master's degree in Industrial Pharmacy from Long Island University, New York, an MBA from the University of Maryland, Baltimore, and postgraduate certifications in finance and management from the London School of Business and Finance.

With over 23 years of expertise in business development, manufacturing operations, supply chain management, and strategic planning, Sadu has been a dedicated member of the Gland Pharma team for the past 22 years.

Per the pharma company, under Sadu's leadership, it has consistently achieved remarkable growth in revenue and profits while expanding its presence across various geographic regions.

Established in 1978, the Hyderabad-based pharmaceutical company has a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets

Gland Pharma is a global generic injectables manufacturer focusing on complex products, serving countries worldwide. It operates primarily under a B2B model and develops, manufactures, and markets sterile injectables. Its range of offerings includes vials, ampoules, pre-filled syringes, lyophilized vials, dry powders: infusions, oncology, and ophthalmic solutions.

Other Major Recent Appointments

India Medtronic, a subsidiary of the global healthcare giant Medtronic, recently appointed Mandeep Singh Kumar as its new VP & MD of its India operations.

Kumar succeeds Michael Blackwell, who has returned to the United States to pursue fresh endeavors.

Per the company, Kumar has experience spanning over 25 years in driving successful growth and business transformations across healthcare, pharmaceutical, and med-tech sectors.

In his new role, Kumar will oversee sales, marketing, and commercial operations for Medtronic in India.

In other developments, Mumbai's L H Hiranandani Hospital appointed Dr Sameer Kulkarni as its new CEO, marking the hospital's 20th anniversary.

Dr Kulkarni succeeds Dr Sujit Chatterjee, who announced his next plans to return to project management and take over as CEO of Sea View Healthcare Management Services. Prior to this role, Dr Kulkarni served as deputy CEO for three months.

Before joining L H Hiranandani Hospital, Dr Kulkarni was the regional director for Paras Healthcare in Gurugram, where he managed five hospitals, including the flagship facility, with a combined capacity of over 1,400 beds. His extensive experience in healthcare management positions him well to lead the hospital into its next phase of growth.